• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by NeuroOne Medical Technologies Corporation

    2/21/25 4:15:41 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care
    Get the next $NMTC alert in real time by email
    S-8 1 ea0231700-s8_neuroone.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on February 21, 2025 

    Registration No. 333-             

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    NeuroOne Medical Technologies Corporation

    (Exact name of registrant as specified in its charter)

     

    Delaware   27-0863354
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    7599 Anagram Dr.,
    Eden Prairie, MN
      55344
    (Address of principal executive offices)   (Zip code)

     

    NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan

    (Full title of the plan)

     

    David Rosa

    President and Chief Executive Officer

    NeuroOne Medical Technologies Corporation

    7599 Anagram Dr.,
    Eden Prairie, MN 55344

    952-426-1383

    (Name, address, and telephone number, including area code, of agent for service)

     

    Copy to:

     

    Phillip D. Torrence, Esq.

    Emily Johns, Esq.

    Honigman LLP

    200 Ottawa Avenue NW, Suite 700

    Grand Rapids, Michigan 49503-2426

    (616) 649-1908

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
      Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    On January 10, 2025, the Board of Directors of NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”, the “Registrant,” “we,” “us,” or “our”) approved the NeuroOne 2025 Equity Incentive Plan (the “2025 Equity Incentive Plan”), subject to approval of the Company’s stockholders. On February 14, 2025, the Company’s stockholders approved the 2025 Equity Incentive Plan. This Registration Statement on Form S-8 (this “Registration Statement”) is being filed with the U.S. Securities and Exchange Commission (the “Commission”) to register the 3,000,000 shares of our common stock, par value $0.001 per share (the “Common Stock”) reserved under the 2025 Equity Incentive Plan, which provides for the grant of equity-based awards in the form of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, directors and consultants.

     

     

     

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information specified in Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the plan covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

     

    1

     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed with the Commission by the Registrant are hereby incorporated by reference in this Registration Statement:

     

    (a)our Annual Report on Form 10-K for the fiscal year ended September 30, 2024, filed with the Commission on December 17, 2024 (including information specifically incorporated by reference herein from the Registrant’s Proxy Statement filed with the Commission on January 21, 2025);

     

    (b)our Quarterly Report on Form 10-Q for the quarter ended December 31, 2024, filed with the Commission on February 12, 2025.

     

    (c)our Current Reports on Form 8-K filed with the Commission on October 31, 2024, November 8, 2024, December 17, 2024 with respect to Item 8.01, January 10, 2025, February 4, 2025, and February 14, 2025, as amended on February 20, 2025.

     

    (d)the description of our Common Stock in our registration statement on Form 8-A filed with the SEC on May 25, 2021 and as amended by any subsequent amendment or report filed for the purpose of updating such description.

     

    In addition, all documents the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, after the filing of this Registration Statement and prior to the filing of a post-effective amendment that indicates that all securities offered hereby have been sold or which deregisters all securities covered hereby then remaining unsold are incorporated by reference in this Registration Statement and are a part hereof from the date of filing of such documents. Notwithstanding anything herein, the Registrant is not incorporating by reference any information furnished under Item 2.02 or Item 7.01 of any Current Report on Form 8-K, unless, and to the extent, specified in any such Current Report on Form 8-K.

     

    Any statement herein or contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, or in any subsequently filed document, which also is or is deemed to be incorporated by reference herein, modifies or supersedes such prior statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute part of this Registration Statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    The Company is incorporated under the laws of the State of Delaware. Section 145 of the Delaware General Corporation Law provides that a Delaware corporation may indemnify any persons who were, are, or are threatened to be made, parties to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was an officer, director, employee or agent of such corporation, or is or was serving at the request of such corporation as an officer, director, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation’s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was illegal. A Delaware corporation may indemnify any persons who were, are, or are threatened to be made, a party to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person is or was a director, officer, employee or agent of such corporation, or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit provided such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation’s best interests except that no indemnification is permitted without judicial approval if the officer or director is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him or her against the expenses (including attorneys’ fees) actually and reasonably incurred.

     

    II-1

     

     

    The Company’s certificate of incorporation provides for the indemnification of its directors to the fullest extent permitted under the Delaware General Corporation Law. The Company’s bylaws provide for the indemnification of its directors and officers to the fullest extent permitted under the Delaware General Corporation Law.

     

    Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duties as a director, except for liability for any:

     

    ●transaction from which the director derives an improper personal benefit;
       
    ●act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
       
    ●unlawful payment of dividends or redemption of shares; or
       
    ●breach of a director’s duty of loyalty to the corporation or its stockholders.

     

    The Company’s certificate of incorporation includes such a provision. Under the Company’s bylaws, expenses incurred by any director or officers in defending any such action, suit or proceeding in advance of its final disposition shall be paid by the Company upon delivery to it of an undertaking, by or on behalf of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not entitled to be indemnified by the Company, as long as such undertaking remains required by the Delaware General Corporation Law.

     

    Section 174 of the Delaware General Corporation Law provides, among other things, that a director who willfully or negligently approves of an unlawful payment of dividends or an unlawful stock purchase or redemption, may be held liable for such actions. A director who was either absent when the unlawful actions were approved or dissented at the time may avoid liability by causing his or her dissent to such actions to be entered in the books containing minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of the unlawful acts.

     

    As permitted by the Delaware General Corporation Law, we have entered into indemnity agreements with each of our directors and executive officers, that require us to indemnify such persons against any and all expenses (including reasonable attorneys’ fees), witness fees, damages, judgments, fines, settlements and other amounts incurred (including expenses of a derivative action) in connection with any action, suit or proceeding, whether actual or threatened, to which any such person may be made a party by reason of the fact that such person is or was a director, an officer or an employee of the Company or any of its affiliated enterprises, provided that such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to our best interests and, with respect to any criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful. The indemnification agreements also set forth certain procedures that will apply in the event of a claim for indemnification thereunder.

     

    The Company has an insurance policy that covers its officers and directors with respect to certain liabilities, including liabilities arising under the Securities Act or otherwise.

     

    Item 7. Exemption from Registration Claimed.

     

    Not Applicable.

     

    II-2

     

     

    Item 8. Exhibits.

     

    Exhibit
    Number
      Description
         
    4.1   Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.4 on the Registrant’s Current Report on Form 8-K filed on June, 29, 2017).
         
    4.2   Certificate of Amendment to Amended and Restated Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.1 on the Registrant’s Current Report on Form 8-K filed on March 31, 2021).
         
    4.3   Amended and Restated Bylaws of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.1 on the Registrant’s Current Report on Form 8-K filed on June 21, 2024.
         
    4.4   NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 on the Registrant’s Current Report on Form 8-K filed on February 20, 2025).
         
    4.5   NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan Form of Restricted Stock Unit Grant Agreement (incorporated by reference to Exhibit 10.2 on the Registrant’s Current Report on Form 8-K filed on February 20, 2025).
         
    4.6   NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan Form of Option Grant Agreement (incorporated by reference to Exhibit 10.3 on the Registrant’s Current Report on Form 8-K filed on February 20, 2025).
         
    5.1*   Opinion of Honigman LLP.
         
    23.1*   Consent of Baker Tilly US, LLP.
         
    23.3*   Consent of Honigman LLP (included in its opinion filed as Exhibit 5.1 to this Registration Statement).
         
    24.1*   Power of Attorney (included after the signature of the Registrant contained on the Signature Page of this Registration Statement).
         
    107*   Filing Fee Table

     

    * Filed herewith.

     

    II-3

     

     

    Item 9. Undertakings.

     

    (a) The Registrant hereby undertakes:

     

      (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

      (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

      (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” table in the effective Registration Statement;

     

      (iii) to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement; and

     

      (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offer thereof.

     

      (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The Registrant hereby undertakes that, for the purpose of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    II-4

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Eden Prairie, State of Minnesota, on this 21st day of February, 2025.

     

      NeuroOne Medical Technologies Corporation
       
      By: /s/ David Rosa
        David A. Rosa
        Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints David A. Rosa and Ronald McClurg, or either of them, as his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any or all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
         
    /s/ David A. Rosa   Chief Executive Officer   February 21, 2025
    David A. Rosa   (Principal Executive Officer) and a Director    
             
    /s/ Ronald McClurg   Chief Financial Officer   February 21, 2025
    Ronald McClurg   (Principal Financial and Accounting Officer)    
             
    /s/ Paul Buckman   Director   February 21, 2025
    Paul Buckman        
             
    /s/ Jeffrey Mathiesen   Director   February 21, 2025
    Jeffrey Mathiesen        
             
    /s/ Edward Andrle   Director   February 21, 2025
    Edward Andrle        

     

    II-5

     

    Get the next $NMTC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NMTC

    DatePrice TargetRatingAnalyst
    5/5/2025$1.45Buy
    Ladenburg Thalmann
    3/29/2022$6.00 → $2.00Buy → Hold
    Craig Hallum
    12/3/2021$5.75Buy
    Alliance Global Partners
    11/15/2021$6.00Buy
    Craig-Hallum
    More analyst ratings

    $NMTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Mcclurg Ronald W. bought $100,000 worth of shares (200,000 units at $0.50), increasing direct ownership by 82% to 444,117 units (SEC Form 4)

      4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

      4/7/25 4:47:21 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • CEO and President Rosa David A bought $50,000 worth of shares (100,000 units at $0.50), increasing direct ownership by 9% to 1,161,289 units (SEC Form 4)

      4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

      4/7/25 4:38:47 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • Volker Christopher bought $105,000 worth of shares (75,000 units at $1.40) (SEC Form 4)

      4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

      12/26/23 4:08:51 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care

    $NMTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ladenburg Thalmann initiated coverage on Numerical Tech with a new price target

      Ladenburg Thalmann initiated coverage of Numerical Tech with a rating of Buy and set a new price target of $1.45

      5/5/25 8:32:14 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • Numerical Tech downgraded by Craig Hallum with a new price target

      Craig Hallum downgraded Numerical Tech from Buy to Hold and set a new price target of $2.00 from $6.00 previously

      3/29/22 8:37:16 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • Alliance Global Partners initiated coverage on NeuroOne Medical Tech with a new price target

      Alliance Global Partners initiated coverage of NeuroOne Medical Tech with a rating of Buy and set a new price target of $5.75

      12/3/21 9:56:11 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care

    $NMTC
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by NeuroOne Medical Technologies Corporation

      SCHEDULE 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

      5/15/25 3:49:33 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • NeuroOne Medical Technologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)

      5/13/25 8:15:21 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by NeuroOne Medical Technologies Corporation

      10-Q - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)

      5/13/25 8:01:14 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care

    $NMTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by NeuroOne Medical Technologies Corporation

      SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

      11/26/24 8:42:10 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by NeuroOne Medical Technologies Corporation

      SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

      11/14/24 3:41:01 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by NeuroOne Medical Technologies Corporation

      SC 13G - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

      2/14/24 4:51:41 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care

    $NMTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary

      EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has strengthened its management team with the appointment of Emily Johns as General Counsel and Corporate Secretary. Dave Rosa, President and CEO of NeuroOne said, "We are excited to welcome Emily to NeuroOne especially after working with her for almost a decade. Her legal acumen and experience navigating dynamic, fast-growing organizations will be invaluable as we continue to scale our business.

      6/3/25 8:30:00 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • NeuroOne to Attend MedInvest's MedTech, AI & Digital Health Conference on June 3-4, 2025

      EDEN PRAIRIE, Minn., May 29, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced its participation in the MedInvest MedTech, AI and Digital Health Conference taking place in San Francisco, CA on June 3-4, 2025. Dave Rosa, President and CEO of NeuroOne will be meeting with investors during the two-day event that will feature informative panel discussions, keynote talks and corporate presentations on medical devices, imaging technologies, diagnostics, AI/data analytics and digital

      5/29/25 1:05:36 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6%

      Filed 510(k)Submission with FDA for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain Ahead of Schedule Company Fully Funded Through at Least Fiscal Year 2026 Following Oversubscribed $8.2 Million Capital Raise EDEN PRAIRIE, Minn., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the second quarter of fiscal year 2025 ended March 31, 2025. Recent Company Highlights Successfully filed FDA submission ahead of schedule for the OneRF® Trigeminal Nerve Ablati

      5/13/25 7:30:00 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care

    $NMTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by General Counsel Johns Emily J.

      4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

      6/3/25 3:45:04 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Johns Emily J.

      3 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

      6/3/25 3:38:03 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • Business Development Director Christianson Mark sold $5,596 worth of shares (8,981 units at $0.62), decreasing direct ownership by 3% to 271,491 units (SEC Form 4)

      4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

      5/23/25 4:03:34 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care

    $NMTC
    Leadership Updates

    Live Leadership Updates

    See more

    $NMTC
    Financials

    Live finance-specific insights

    See more
    • NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary

      EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has strengthened its management team with the appointment of Emily Johns as General Counsel and Corporate Secretary. Dave Rosa, President and CEO of NeuroOne said, "We are excited to welcome Emily to NeuroOne especially after working with her for almost a decade. Her legal acumen and experience navigating dynamic, fast-growing organizations will be invaluable as we continue to scale our business.

      6/3/25 8:30:00 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical Advisor

      Significant Neurological Expertise to Help Drive Clinical Development Strategy and Growth with New Technologies EDEN PRAIRIE, Minn., May 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has appointed Parag G. Patil, M.D., Ph.D., as Chief Medical Advisor (CMA), after serving on the company's Scientific Advisory Board since 2018. Dr. Parag G. Patil is a neurosurgeon-engineer with 20 years' experience serving patients and advancing innovative therapies to alleviate neurol

      5/12/25 8:30:00 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      Volker strengthens existing management team in areas of commercialization, business development, and reimbursement EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has appointed medtech executive Christopher R. Volker as Chief Operating Officer. Mr. Volker joins NeuroOne from Abbott Laboratories which acquired Cardiovascular Systems, Inc. in April 2023. Mr. Volker held the role of Vice President and General Manager of International at

      11/14/23 5:15:00 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6%

      Filed 510(k)Submission with FDA for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain Ahead of Schedule Company Fully Funded Through at Least Fiscal Year 2026 Following Oversubscribed $8.2 Million Capital Raise EDEN PRAIRIE, Minn., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the second quarter of fiscal year 2025 ended March 31, 2025. Recent Company Highlights Successfully filed FDA submission ahead of schedule for the OneRF® Trigeminal Nerve Ablati

      5/13/25 7:30:00 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • NeuroOne® to Report Second Quarter Fiscal Year 2025 Financial Results on Tuesday, May 13 at 8:30 a.m. Eastern Time

      EDEN PRAIRIE, Minn., May 01, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal second quarter ended March 31, 2025, before market open on May 13, 2025. Management will host an investor conference call and webcast at 8:30 a.m. Eastern time on Tuesday, May 13, 2025, to discuss the Company's second quarter fiscal year 2025 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the f

      5/1/25 9:55:00 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • NeuroOne® Reports First Quarter Fiscal Year 2025 Financial Results and Provides Corporate Update

      Total revenue of $6.3M Includes $3.3 Million of Product Revenue in Addition to a One-Time Upfront Payment of $3.0 Million in License Revenue from Zimmer Biomet EDEN PRAIRIE, Minn., Feb. 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the first quarter fiscal year 2025 ended December 31, 2024. First Quarter Financial Highlights Product revenue increased 235% to $3.3 million in the first quarter of fiscal year 2025, compared to $1.0 million in the first quarter of fiscal

      2/12/25 8:00:00 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care